舒肝解郁胶囊联合氨磺必利治疗肝脾不和型精神分裂症的临床疗效观察

doi:10.3760/cma.j.issn.1007-1245.2022.04.025

国际医药卫生导报 ›› 2022, Vol. 28 ›› Issue (4): 545-547.DOI: 10.3760/cma.j.issn.1007-1245.2022.04.025

舒肝解郁胶囊联合氨磺必利治疗肝脾不和型精神分裂症的临床疗效观察

胡亚丽

三门峡市康复医院心身医学科，三门峡　472000

收稿日期:2021-10-27 出版日期:2022-02-15 发布日期:2022-03-15
通讯作者: 胡亚丽，Email：yinpin0022333@163.com

Clinical effect of Shugan Jieyu capsules combined with amisulpride in the treatment of schizophrenia of liver-spleen discordance

Hu Yali

Department of Psychosomatic Medicine, Sanmenxia Rehabilitation Hospital, Sanmenxia 472000, China

Received:2021-10-27 Online:2022-02-15 Published:2022-03-15
Contact: Hu Yali，Email: yinpin0022333@163.com

摘要/Abstract

摘要： 目的　探讨舒肝解郁胶囊联合氨磺必利治疗肝脾不和型精神分裂症的临床疗效。方法　选取2019年3月至2021年3月在三门峡市康复医院确诊的85例肝脾不和型精神分裂症患者，简单随机将其分为观察组和对照组。将采用氨磺必利治疗的42例患者纳入对照组，将采用舒肝解郁胶囊联合氨磺必利治疗的43例患者纳入观察组，均持续治疗6周。观察组男23例，女20例，年龄（40.35±6.17）岁；对照组男18例，女24例，年龄（41.27±6.24）岁。评估观察组和对照组患者治疗后的临床疗效，比较两组患者治疗前后的中医症候积分及治疗期间的不良反应发生率。计量资料组间比较采用独立样本t检验，组内治疗前后比较采用配对t检验，计数资料采用χ²检验。结果　观察组治疗有效率为95.35%（41/43），高于对照组80.95%（34/42）（P<0.05）。治疗6周后，观察组胁腹胀痛、食少纳呆及神疲懒言症候积分分别为（2.08±0.28）分、（1.96±0.37）分及（2.17±0.21）分，低于对照组的（2.23±0.22）分、（2.17±0.24）分及（2.32±0.27）分（均P<0.05）。观察组患者治疗期间不良反应发生率为13.95%（6/43）与对照组的9.52%（4/42）比较差异无统计学意义（P>0.05）。结论　舒肝解郁胶囊联合氨磺必利治疗可以明显提高肝脾不和型精神分裂症患者的临床疗效。

关键词: 舒肝解郁胶囊, 氨磺必利, 肝脾不和, 精神分裂症

Abstract: Objective　To explore the clinical effect of Shugan Jieyu capsules combined with amisulpride in the treatment of schizophrenia of liver-spleen discordance. Methods　A total of 85 patients with schizophrenia of liver-spleen discordance confirmed in Sanmenxia Rehabilitation Hospital were enrolled between March 2019 and March 2021. They were simply randomly divided into an observation group and a control group, including 42 cases treated with amisulpride in the control group and 43 cases treated with Shugan Jieyu capsules and amisulpride in the observation group. All patients were continuously treated for 6 weeks. There were 23 males and 20 females in the observation group, with an age of (40.35±6.17) years old; there were 18 males and 24 females in the control group, with an age of (41.27±6.24) years old. The clinical curative effect in both groups was evaluated after treatment. The scores of traditional Chinese medicine (TCM) syndromes before and after treatment and the incidence of adverse reactions during treatment were compared between the two groups. Independent sample t test was used for inter-group comparison of the measurement data, paired t test was used for intra-group comparison of the measurement data, and χ² test was used for the count data. Results　The effective rate of the observation group was 95.35% (41/43), which was higher than that of the control group [80.95% (34/42)] (P<0.05). After 6 weeks of treatment, the scores of flank distension and pain, poor appetite, and fatigue and laziness in the observation group were (2.08±0.28) points, (1.96±0.37) points, and (2.17±0.21) points, respectively, which were lower than those in the control group [(2.23±0.22) points, (2.17±0.24) points, and (2.32±0.27) points] (all P<0.05). The incidence of adverse reactions was 13.95% (6/43) in the observation group and 9.52% (4/42) in the control group, without statistically significant difference (P>0.05). Conclusion　Shugan Jieyu capsules combined with amisulpride can significantly improve the clinical curative effect in patients with schizophrenia of liver-spleen discordance.

Key words: Shugan Jieyu capsules, Amisulpride, Liver-spleen discordance, Schizophrenia

胡亚丽. 舒肝解郁胶囊联合氨磺必利治疗肝脾不和型精神分裂症的临床疗效观察[J]. 国际医药卫生导报, 2022, 28(4): 545-547.

Hu Yali.

Clinical effect of Shugan Jieyu capsules combined with amisulpride in the treatment of schizophrenia of liver-spleen discordance [J]. International Medicine and Health Guidance News, 2022, 28(4): 545-547.

参考文献

[1] 张丽,李春燕,武晓静.多学科联合干预对精神分裂症患者自我管理行为的影响[J].国际医药卫生导报,2019,25(2):214-218. DOI:10.3760/cma.j.issn.1007-1245.2019. 02.014.

[2] Silva MA, Restrepo D. Functional recovery in schizophrenia[J]. Rev Colomb Psiquiatr (Engl Ed), 2019, 48(4):252-260. DOI: 10.1016/j.rcp.2017.08.004.

[3] 李旋,刘登堂.首次治疗抵抗精神分裂症患者的药物选择[J].临床精神医学杂志,2020,30(3):214-216. DOI:10.3969/j.issn.1005-3220.2020.03.023.

[4] 张志勇,原富强,程德君.奥氮平联合氨磺必利治疗精神分裂症的效果及其对睡眠和认知功能的影响[J].国际精神病学杂志,2020,47(1):43-45,57. DOI: 10.13479/j.cnki.jip.2020.01.012.

[5] 刘永阔,徐峰,魏华,等.徐峰教授从肝脾不和论治高血压[J].世界中西医结合杂志,2019,14(9):1240-1243. DOI:10.13935/j.cnki.sjzx.190913.

[6] 司夏樱,任丽娜,岳秀宁,等.舒肝解郁胶囊联合重复经颅磁刺激治疗抑郁症的疗效评价[J].中华航海医学与高气压医学杂志,2019,26(4):328-331. DOI:10.3760/cma.j.issn. 1009-6906.2019.04.001.

[7] 中华医学会放射学分会磁共振学组.精神分裂症MR脑结构成像技术规范化应用中国指南[J].中华放射学杂志,2019,53(3):170-176. DOI:10.3760/cma.j.issn.1005-1201. 2019.03.003.

[8] 梁茂新,高天舒.«中药新药临床研究指导原则»脏腑诸证考察与分析[J].中国中医基础医学杂志,2008,14(5):330-331,342. DOI:10.3969/j.issn.1006-3250.2008.05.005.

[9] Lin CH, Lin HS, Lin SC, et al. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia[J]. Acta Psychiatr Scand, 2018, 137(2):98-108. DOI: 10.1111/acps.12849.

[10] 黄蓓.«证候类中药新药临床研究技术指导原则»发布[J].中医药管理杂志,2018, 26(21):107. DOI:10.16690/j.cnki.1007-9203.2018.21.056.

[11] 王海林,陈敏,侯波,等.痛泻要方联合电针治疗肝脾不和型溃疡性结肠炎临床研究[J].四川中医,2020,38(7):124-127.

[12] 项锋,叶继锋,侯齐书.基于PCA和PLS-DA算法的不同生长阶段贯叶金丝桃药材HPLC指纹图谱研究[J].药物分析杂志,2020,40(3):568-576. DOI:10.16155/j.0254-1793. 2020.03.23.

[13] 高彦宇,李文慧,寇楠,等.刺五加化学成分和药理作用研究进展[J].中医药信息,2019,36(2):113-116. DOI:10.19656/j.cnki.1002-2406.190060.

[14] 傅松年,王江涛,罗福祥,等.贯叶金丝桃提取物对慢性不可预知性温和应激致小鼠抑郁的改善作用[J].中华行为医学与脑科学杂志,2019,28(10):915-920. DOI:10.3760/cma.j.issn.1674-6554.2019.10.010.

[15] 池林,赵勇,陈红玉,等.舒肝解郁胶囊辅助治疗精神分裂症临床疗效和安全性的Meta分析[J].中医药导报,2020,26(2):76-81. DOI:10.13862/j.cnki.cn43-1446/r.2020. 02.022.

舒肝解郁胶囊联合氨磺必利治疗肝脾不和型精神分裂症的临床疗效观察

Clinical effect of Shugan Jieyu capsules combined with amisulpride in the treatment of schizophrenia of liver-spleen discordance

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics